US 12,109,209 B2
Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease
Hiroshi Nagase, Ibaraki (JP); Hideaki Fujii, Tokyo (JP); Akiyoshi Saitoh, Tokyo (JP); Eriko Nakata, Saitama (JP); Masaaki Hirose, Saitama (JP); Isao Ooi, Saitama (JP); and Kohei Hayashida, Saitama (JP)
Assigned to NIPPON CHEMIPHAR CO., LTD., Tokyo (JP)
Filed by NIPPON CHEMIPHAR CO., LTD., Tokyo (JP)
Filed on Dec. 15, 2022, as Appl. No. 18/081,842.
Application 18/081,842 is a continuation of application No. 16/333,373, granted, now 11,633,392, previously published as PCT/JP2017/033459, filed on Sep. 15, 2017.
Claims priority of application No. 2016-203925 (JP), filed on Sep. 16, 2016.
Prior Publication US 2023/0132191 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/485 (2006.01); A61P 25/04 (2006.01); A61P 25/06 (2006.01); A61P 25/22 (2006.01)
CPC A61K 31/485 (2013.01) [A61P 25/04 (2018.01); A61P 25/06 (2018.01); A61P 25/22 (2018.01)] 9 Claims
 
1. A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, comprising:
administering to the subject an effective amount of a compound selected from the group consisting of:
2-((1S,3aR,5aS,6R,11bR, 11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 1-oxide;
3-((1S,3aR,5aS,6R,11bR, 11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one;
6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one;
5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one;
6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one; and
6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridazin-3(2H)-one;
or a pharmaceutically acceptable salt thereof.